ClinicalTrials.gg
Enrolling by invitationNCT06758518CRSUpdated May 5, 2026

Study of the Carpal Tunnel Syndrome in Relation to Stress and Depression Among Medical Students

An observational study in Carpal Tunnel Syndrome (CTS), sponsored by University of Ioannina. Enrolling by invitation at 1 site in Greece. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by University of Ioannina · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
180
Sex
All
01

Study summary

Participants will undertake validation of the median nerve and their anxiety and depression levels. Possible correlation will be searched.

Read the detailed description

Medical students of the University of Ioannina will be submitted to ultrasound of the medial nerve as to assess its surface. Those with pathological findings will undertake a non-interventional electromyography test. Afterwards they will complete anonymously two validated tests regarding depression and anxiety (Yung ans STAI scales). Statistical analysis will be conducted with the question of correlation between median nerve dysfunction and psychiatric disorders.

02

Conditions studied

  • Carpal Tunnel Syndrome (CTS)

Keywords

  • carpal tunnel syndrome
  • anxiety
  • depression
  • medical students
03

In context

Carpal Tunnel Syndrome

591 studies on the registry are indexed under Carpal Tunnel Syndrome; 133 are open to participants now.

This study's planned enrollment of 180 is above the median of 92 across 131 observational studies indexed under Carpal Tunnel Syndrome.

Browse Carpal Tunnel Syndrome studies →

Lead sponsor

University of Ioannina is the lead sponsor of 53 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

medical students of the university of ioannina

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • medical students

Exclusion criteria

Exclusion Criteria:

  • known pathology of the carpal joint
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
180 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • With carpal tunnel syndrome

    Subjects with medial nerve disorders (clinical or ultrasound surface of the nerve over 12mm2).

    Other: No Interventions

Interventions

  • OtherNo Interventions

    there will be no intervention

    Also known as: no intervention

06

What researchers measure

Primary outcomes

  1. Correlation of median nerve disorder with anxiety and/or depression

    the measurement of the median nerve surface will be examined for correlation with depression or anxiety through self- questionnaires

    Time frame: 1 month

07

Study locations

1 site
  • Medical School, University of Ioannina
    Ioannina, Epirus 45332, Greece
08

References and documents

Individual participant data

Plan to share: No — No personal data of the students will be announced. All the study will be completed anonymoously.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2025 to primary completion in Jan 2025, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 27, 2024
First posted
Jan 3, 2025
StartActual
Jan 1, 2025
Primary completionActual
Jan 15, 2025
CompletionEst.
Apr 30, 2026
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06758518
Lead sponsor
University of Ioannina
Responsible party
AIKATERINI MARINI (MD, PhD, Researcher, University of Ioannina) — Principal investigator
First posted
Jan 3, 2025
Start date
Jan 1, 2025
Primary completion
Jan 15, 2025
Completion
Apr 30, 2026 (estimated)
Last update
May 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion